{"id":13401,"date":"2010-10-27T10:40:00","date_gmt":"2010-10-27T08:40:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pfizer-ratiopharma-sotto-la-lente-antitrust\/"},"modified":"2010-10-27T10:40:00","modified_gmt":"2010-10-27T08:40:00","slug":"pfizer-ratiopharma-sotto-la-lente-antitrust","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-ratiopharma-sotto-la-lente-antitrust\/","title":{"rendered":"Pfizer-Ratiopharma under the Antitrust lens"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-font-kerning: 18.0pt; mso-fareast-language: IT; mso-bidi-font-weight: bold\"><font size=\"3\"><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-font-kerning: 18.0pt; mso-fareast-language: IT; mso-bidi-font-weight: bold\"><font size=\"3\"><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-font-kerning: 18.0pt; mso-fareast-language: IT; mso-bidi-font-weight: bold\"><font size=\"3\">The ongoing challenge of Big-Pharma against the irruption of generics ends up in the sights of the Italian Antitrust. Pfizer, according to the documentation collected by the Authority, &quot;arguably requested and obtained an extension of the patent coverage, through the request for a divisional patent which was followed by the request for a complementary protection certificate aimed at extending the protection until 2011&quot;. The active ingredient indicted is Latanoprost and the investigation that follows the EU commission&#039;s investigation into the sector stems from remarks raised by Ratiopharm, a German company that produces generics, which curiously Pfizer itself had attempted to acquire last spring. But it had been beaten to a close by the giant of generics, the Israeli Teva.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><em style=\"mso-bidi-font-style: normal\"><span style=\"font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; mso-fareast-font-family: 'Times New Roman'; mso-font-kerning: 18.0pt; mso-fareast-language: IT; mso-bidi-font-weight: bold\">Finance&amp;Markets \u2013 27\/10\/2010&nbsp; <img loading=\"lazy\" decoding=\"async\" class=\"rg_hi\" id=\"rg_hi\" style=\"width: 68px; height: 61px\" height=\"90\" alt=\"\" width=\"90\" data-width=\"90\" data-height=\"90\" src=\"http:\/\/t1.gstatic.com\/images?q=tbn:ANd9GcSBHyq8JJxnurZXAL6ppB3e5NZ0Q4i6dx2LbV9DQTBeiDhS_po&amp;t=1&amp;usg=__l1m6Ut6Xe7a0y0We4W53cRD0OFs=\" \/><\/span><\/em><em style=\"mso-bidi-font-style: normal\"><span style=\"font-size: 10pt; line-height: 115%\"><\/p>\n<p><\/span><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>La sfida continua delle Big-Pharma contro l&rsquo;irrompere dei generici finisce nel mirino dell&rsquo;Antitrust italiano. Pfizer, secondo la documentazione raccolta dall&rsquo;Autorit&agrave;, &laquo;avrebbe artatamente richiesto e ottenuto una proroga della copertura brevettuale, attraverso la richiesta di un brevetto divisionale cui &egrave; seguita la richiesta di un certificato di protezione complementare finalizzato ad estendere fino al 2011 la &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13401"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13401\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}